December 2019 Newsletter
Canadian Biosimilar Stakeholder Consultation Survey Open Until January 13 The Canadian Agency for Drugs and Technologies and Health (CADTH), in conjunction with the pan-Canadian Pharmaceutical Alliance (pCPA) – is leading a consultation on the use and implementation of biosimilars. ASBM encourages Canadian stakeholders- particularly those in the patient and physician communities who are concerned with […]